Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 24;8(11):e0573.
doi: 10.1097/HC9.0000000000000573. eCollection 2024 Nov 1.

Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis

Alvi Husni Islam  1 , Luis Antonio Díaz  2   3 , Francisco Idalsoaga  1   2 , Leonardo Guizzetti  4 , Rokhsana Mortuza  1 , Winston Dunn  5 , Ashwani K Singal  6 , Douglas Simonetto  7 , Carolina Ramirez-Cadiz  8 , Wei Zhang  9 , Steve Qian  10 , Joaquín Cabezas  11 , Shiv K Sarin  12 , Rakhi Maiwall  12 , Prasun K Jalal  13 , Fatima Higuera-De La Tijera  14 , Lubomir Skladany  15 , Natalia Bystrianska  15 , Diego Rincon  16 , Kristina R Chacko  17 , Meritxell Ventura Cots  18 , Guadalupe Garcia-Tsao  19 , Juan G Abraldes  20 , Patrick S Kamath  7 , Marco Arrese  2 , Vijay Shah  7 , Ramon Bataller  21   22 , Juan Pablo Arab  2   23
Affiliations

Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis

Alvi Husni Islam et al. Hepatol Commun. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ashwani K. Singal consults and owns stock in Pleiogenix. He advises and is on the speaker’s bureau for the CLD Foundation. He consults for AGA. He advises Durect, Gastroendo News, and AASLD. He is on the speaker’s bureau for Medscape Gastroenterology. He received grants from NIH. Douglas Simonetto consults for Mallinckrodt, BioVie, Pharma Inc., Resolution Therapeutics, Iota, Evive, and AstraZeneca. Joaquin Cabezas advises and received grants from Gilead. He received grants from Abbvie. Lubomir Skladany consults, advises, is on the speaker’s bureau, and received grants from Astellas. He consults, advises, and is on the speaker’s bureau for Gilead. He is on the speaker’s bureau and received grants from Promed and WORWAG. He received grants from FALK. Juan G. Abraldes consults for 89bio, Boehringer Ingelheim, AstraZeneca, Agomab, Boston Pharmaceuticals, and Novo Nordisk. He received grants from Cook and Gilead. Ramon Bataller consults for GlaxoSmithKline, Novo Nordisk, Boehringer Ingelheim, and Resolution Therapeutics. He is on the speaker’s bureau for Gilead and Abbvie. The remaining authors have no conflicts to report.

Figures

None
Graphical abstract
FIGURE 1
FIGURE 1
Kaplan-Meier curve of survival in patients with severe alcohol-associated hepatitis by steroid type (prednisone, prednisolone, and methylprednisolone).
See this image and copyright information in PMC

References

    1. Bataller R, Arab JP, Shah VH. Alcohol-associated hepatitis. N Engl J Med. 2022;387:2436–2448. - PubMed
    1. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. . Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372:1619–1628. - PubMed
    1. Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. . Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo—A meta-analysis of individual data from controlled trials. Gastroenterology. 2018;155:458–468.e8. - PubMed
    1. Arab JP, Díaz LA, Baeza N, Idalsoaga F, Fuentes-López E, Arnold J, et al. . Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021;75:1026–1033. - PMC - PubMed
    1. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: Current challenges and future directions. Clin Gastroenterol Hepatol. 2014;12:555–564; quiz e31–e32. - PMC - PubMed

LinkOut - more resources